Skip to content
WeighLab

Effecty vs PepHaūs

Compare the prices, treatment options and tradeoffs that matter before you choose a GLP-1 program.

By The WeighLab Bench. Provider verification dates appear below.

We may earn a commission if you sign up through a provider link, at no extra cost to you. Compensation does not change scores. How we earn money.

The comparison in brief

Effecty has the higher Cost-Efficiency Index: 86/100 versus 85/100. That is a value comparison under our published methodology, not a measure of medical suitability or a guarantee of results.

The better fit depends on what is included in your quote. A lower advertised price can require prepayment, apply to a starting dose or leave out a separate fee.

How the comparison is scored

Costs & coverage

Published prices with their terms intact. Annual estimates account for billing frequency and known fixed required fees; they are not a treatment quote.

Effecty

PepHaūs

Semaglutide / month
Effecty: $160/mo
PepHaūs: $152/mo
Tirzepatide / month
Effecty: $240/mo
PepHaūs: $246/mo
Semaglutide / year (modeled)
Effecty: $1,920
PepHaūs: $1,824
Tirzepatide / year (modeled)
Effecty: $2,880
PepHaūs: $2,952
State availability
Effecty: All 50 states
PepHaūs: All 50 states
Oral / sublingual option listed
Effecty: Not listed
PepHaūs: Not listed
Brand-name access listed
Effecty: Yes
PepHaūs: Not confirmed
Provider facts checked
Effecty: See full review
PepHaūs: See full review

Comparing different billing plans? See what a GLP-1 monthly price can leave out, or calculate the monthly cost.

Which program fits your priorities?

The strengths and limitations behind each provider's score. Read the full review before deciding.

Effecty

People who want competitive compounded pricing but also the option to step up to brand-name, verified and nationwide.

Reasons to consider it

  • Both molecules disclosed at competitive prices with all-50 access
  • Offers FDA-approved brand-name access alongside compounded
  • LegitScript-certified pharmacy

What to weigh up

  • Per-month cost is mid-market, not budget-tier
  • No oral/sublingual option

Compounded drugs are not FDA-approved. Understand the medication options.

Check Effecty pricing Read the full Effecty review

PepHaūs

People who want a verified all-50 program with both molecules disclosed and will pay mid-market for the peace of mind.

Reasons to consider it

  • Both molecules disclosed at flat prices with nationwide all-50 access
  • LegitScript-certified pharmacy behind the program
  • Predictable pricing that's straightforward to model for a year

What to weigh up

  • $152/$246 is mid-market — undercut on raw cost by several verified all-50 rivals
  • Compounded only — no brand-name or oral option

Compounded drugs are not FDA-approved. Understand the medication options.

Check PepHaūs pricing Read the full PepHaūs review

Explore the six scoring factors

Scores run from 0 to 100. A higher factor score reflects our published value criteria; it is not a clinical endorsement.

EffectyPepHaūs
Normalized Cost/Month
Effecty:
80/100
PepHaūs:
80/100
Price Transparency
Effecty:
86/100
PepHaūs:
86/100
Nationwide Access
Effecty:
96/100
PepHaūs:
96/100
Formulation Options
Effecty:
86/100
PepHaūs:
78/100
Clinical Oversight
Effecty:
88/100
PepHaūs:
86/100
Contract Flexibility
Effecty:
82/100
PepHaūs:
82/100

Before you sign up

  • Confirm your totalAsk about dose changes, membership, labs, shipping and cancellation terms.
  • Check treatment accessState coverage and medical eligibility can differ by medication and formulation.
  • Understand the medicationCompare compounded and brand-name options. Compounded drugs are not FDA-approved.

Keep comparing

Alternatives to EffectyAlternatives to PepHaūs
More provider matchups
CoreAge Rx vs EffectyCoreAge Rx vs PepHaūs
Choose a different comparison

Provider information reflects public disclosures at the verification dates shown. Prices and availability change; confirm current terms before paying. This comparison is for information, not medical advice. A licensed clinician determines whether treatment is appropriate.